Johnson & Johnson v. Samsung Bioepis Co Ltd
Third Circuit: Samsung Bioepis's Remicade Biosimilar Does Not Infringe J&J Patents
Third Circuit · 2026-04-14 · Defendant Win · Impact: 75/100
Johnson & Johnson v. Samsung Bioepis Co Ltd, decided by Third Circuit on April 14, 2026, resulted in a defendant win outcome. The Third Circuit affirmed the District of Delaware's decision, holding th...